Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral FMT in Multiple Sclerosis
NCT04096443Phase 1Completed
- Sponsor
- Griffin Hospital
- Start
- Oct 2019
- Primary completion
- Dec 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fecal microbiome transplant in multiple sclerosis (MS), sponsored by Griffin Hospital. Primary endpoint: Change in engraftment of donor microbiome in stool samples. Started Oct 2019; status: completed.
02
Drugs
fecal microbiome transplant
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04096443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04096443.